The mechanism matters more than the marketing. On October 16, the Department of Health and Human Services sent the White House a notice titled “Interim Access Policy for Compounding Using Certain Peptides,” according to the American Med Spa Association, which tracks the filing. It is not a rule and not a drug approval. It is a plan for the FDA to use enforcement discretion — to decide, case by case, not to act against pharmacies that make a handful of peptides the agency itself flagged three years ago as unsafe to compound. The notice is still at the White House’s Office of Management and Budget, a review step with no statutory deadline, so there is no date by which it must emerge.
Peptides are short chains of amino acids, the same building blocks that make proteins, as Dr. Alison Dempsey of Weill Cornell Medicine put it in an interview with CNBC Make It. Some occur naturally in the body — insulin, endorphins. Some are synthesized and FDA-approved, including the GLP-1 drugs sold as Ozempic and Wegovy. Others, sold online and in wellness clinics as BPC-157, GHK-Cu, TB-500 and similar compounds, share none of the GLP-1s’ regulatory or clinical track record. “A compound’s status as a peptide doesn’t mean it’s close to Ozempic in any way, shape or form,” Dr. Pieter Cohen of Harvard Medical School told CNBC, “in terms of both its chemical structure or its effects on the human body.”
Two ways to reach a pharmacy shelf
Under Section 503A of the Food, Drug and Cosmetic Act, a compounding pharmacy can mix an unapproved ingredient into a drug for an individual patient only if the FDA has decided the ingredient belongs on its “bulks list.” The agency sorts nominated ingredients into Category 1, eligible for compounding while under review, and Category 2, those it says “may present significant safety risks.” In September 2023 the FDA put BPC-157 and roughly a dozen other peptides into Category 2, citing risks of contamination, allergic reaction and tumor growth. Getting an ingredient moved onto the bulks list formally — the durable route — takes years and multiple rounds of public comment. Enforcement discretion is the shortcut: the FDA simply stops enforcing the Category 2 restriction for named substances, without changing the underlying rule, without approving anything, and without the peptide ever becoming an approved drug.
| From | To | How |
|---|---|---|
| 2023: FDA lists BPC-157 as Category 2 (cites contamination, allergy, tumor risk) | Feb 2026: Kennedy tells Rogan he's 'a big fan' | Kennedy orders review |
| Feb 2026: Kennedy tells Rogan he's 'a big fan' | Jul 2026: advisory panel votes 6 of 7 yes (FDA's own scientists opposed all seven) | |
| Jul 2026: advisory panel votes 6 of 7 yes (FDA's own scientists opposed all seven) | Oct 16, 2026: HHS sends policy to OMB (enforcement discretion, not approval) | recommendation |
| Oct 16, 2026: HHS sends policy to OMB (enforcement discretion, not approval) | Pharmacies compound BPC-157 etc. (purity certification, side-effect reporting proposed) | pending, no deadline |
Based on American Med Spa Association; FDA
The chain from safety flag to access policy runs through Health Secretary Robert F. Kennedy Jr., who has used peptides personally and said so on The Joe Rogan Experience in February: “I’m a big fan of peptides,” he told Rogan, according to CBS News. “I’ve used them myself and with really good effect on a couple of injuries.” He also told Rogan the FDA would act within weeks and directed the agency to reconsider the Category 2 list — the start of a process that took closer to five months than two weeks.
On July 23 and 24, the FDA’s 14-member Pharmacy Compounding Advisory Committee took up seven peptides over two days. FDA staff’s written briefing opposed adding any of the seven to the bulks list, according to ABC News, citing meeting materials from the July 23-24 session. The committee voted anyway: 8-6 with one abstention for BPC-157, KPV and TB-500; 7-5 with two abstentions for MOTS-C; majorities also backed Epitalon and Semax. A seventh candidate, emideltide (also called DSIP), was voted down. Six of seven is a recommendation, not a decision — the final call on the bulks list rests with Kennedy’s department, and the committee is scheduled to take up a further round of peptides in February 2027. The interim policy now at the White House is reportedly meant to cover some of the same six while that slower process runs.
Becker’s Hospital Review reported on October 22 that the draft under White House review has picked up more conditions than first expected: pharmacies would have to certify the purity and identity of what they compound and report serious side effects. Those are paperwork requirements, not clinical ones. Nothing in the reported draft requires a randomized trial, a control group, or a minimum number of human subjects before a pharmacy can sell the peptide to a patient.
What the human evidence actually says
For BPC-157 specifically, the human evidence is thin by any standard a drug regulator normally applies. A 2025 pilot study on intravenous BPC-157 safety, published and indexed on PubMed, enrolled two patients. A 2021 retrospective review of chronic knee pain covered 16 patients, 14 of whom (87.5%) reported relief — a case series, not a controlled trial. A 2024 pilot study on interstitial cystitis treated 12 women by injection into the bladder wall; all 12 reported improvement and no short-term adverse effects were recorded. A Phase 1 safety and pharmacokinetics trial in 42 healthy volunteers was registered in 2015 and never reported results. None of these studies used a placebo arm. Dr. Caleb Alexander of the Johns Hopkins Bloomberg School of Public Health summed up the problem to CNBC: “There are a few reasons why, but one of the main ones is the absence of evidence,” including robust human safety and efficacy data.
A randomized, placebo-controlled test is finally underway: a Phase 2 trial, registered on ClinicalTrials.gov, is testing whether BPC-157 speeds recovery from a grade II hamstring strain over 14 days of injections alongside standard rehabilitation. It is the kind of trial — comparator arm, defined injury, defined endpoint — that the 2023 Category 2 listing and the July advisory panel both said was missing. It has not reported results. The policy moving through the White House does not wait for it.
My recommendation is not to use any of the novel, unstudied injectable peptides because we simply do not know if they work. And if they do work, if they’re safe.
That is Cohen’s blunt summary to CNBC, and it extends past BPC-157 to the wider market the interim policy does not touch: peptides sold directly to consumers outside any pharmacy, compounding or otherwise. Alexander told CNBC those products carry marketing claims — longevity, sleep, immunity, sexual function — with no clinical backing behind any of them. Buying on that gray market, Cohen said, can mean getting an entirely different compound or dose than advertised, sometimes contaminated with bacteria or other material.
Becker’s Hospital Review, tracking cryptocurrency payment flows to gray-market peptide vendors, found inflows on pace to cross a $100 million annual run rate in 2026, after growing for six straight quarters from roughly $1 million a quarter in 2024. Over the same period, spending on independent third-party purity testing fell by an estimated 88% per buyer even as the number of tests performed rose, with buyers increasingly relying on vendor-supplied certificates that often skip sterility screening. Becker’s also identified two suppliers that had previously been named as fentanyl and amphetamine-precursor sources to cartels and darknet markets before rebranding to sell peptides to retail buyers, using the same contact details as before.
The chart shows a roughly 25-fold rise in annualized gray-market inflow over two years, against a backdrop of falling, not rising, independent verification of what is actually in the vial. An interim access policy built on enforcement discretion does nothing to that market directly — it governs licensed compounding pharmacies, not overseas sellers on Telegram. What it would do, if finalized as reported, is let a regulated channel sell some of the same molecules the gray market already sells, on the strength of a certification about purity rather than a trial about effect. The FDA’s own advisory committee could revisit a further batch of peptides as early as February 2027; the OMB review that determines whether this round of six reaches pharmacy shelves first has no clock on it at all.